Nabriva Therapeutics plc (NBRV)

Etorro trading 970x250

About Nabriva Therapeutics plc

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. Address: 25-28 North Wall Quay, Dublin, Ireland, 1

Nabriva Therapeutics plc News and around…

Latest news about Nabriva Therapeutics plc (NBRV) common stock and company :

Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021
15 Oct, 2021 Yahoo! Finance

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentation at CHEST 2021, the annual meeting of the American College of CHEST Physicians, which will be held virtually October 17-20. On behalf of Nabriva, Dr. Thomas M. File, MD, MS, FCCP will participate in a live o

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)
04 Oct, 2021 Yahoo! Finance

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today published the first data to demonstrate the anti-inflammatory activity of XENLETA® (lefamulin). The nonclinical study, entitled “Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a li

Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Oct, 2021 Yahoo! Finance

DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option to purchase an aggregate of 100,000 ordinary shares of Nabriva Therapeutics as an inducement to Christopher Naftzger, Nabriva’s newly appointed General Counsel. This grant was awarded pursuant to the N

Lab notes: Onconova completes $21M stock sale; Waypoint gets $1.7M investment
01 Oct, 2021 Yahoo! Finance

This week's look at the Philadelphia region's life sciences industry includes a public stock sale, a private stock sale, a multimillion-dollar research grant and more. Here's the rundown: Onconova The Bucks County-based biopharmaceutical company raised $21 million in a public stock offering. Onconova (NASDAQ: ONTX) of Newtown sold 5 million shares of its common stock at $4.20 per share.

Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer
01 Oct, 2021 Yahoo! Finance

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the appointment of Dr. Christine Guico-Pabia, M.D., MBA, MPH as Chief Medical Officer (CMO) effective October 1, 2021. “We are very pleased to have Christine join our senior leadership team. Christine brings a well-rounded profile

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
30 Sep, 2021 Yahoo! Finance

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021. AWG members are presenting a total of 23 poster presentations and 3 oral abstract presentations.

Nabriva Therapeutics to Present Data at IDWeek 2021
24 Sep, 2021 FinancialContent
Interesting NBRV Call Options For November 19th
17 Sep, 2021 FinancialContent

Investors in Nabriva Therapeutics plc (NBRV) saw new options begin trading this week, for the November 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NBRV options chain for the new November 19th contracts and identified the following call contract of particular interest.

4 Penny Stocks Insiders Are Buying
16 Sep, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Nabriva Therapeutics, Vizient Inks Xenleta Distribution Pact
09 Sep, 2021 FinancialContent

Nabriva Therapeutics Plc(NASDAQ: NBRV)entered an agreementwithVizientto offer Xenleta as a contracted ...

Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient’s Pharmacy Network Program
09 Sep, 2021 FinancialContent

- Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumonia (CABP)

Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia
08 Sep, 2021 FinancialContent
Return on Capital Employed Overview: Nabriva Therapeutics
02 Sep, 2021 FinancialContent

According to data from Benzinga Pro, during Q2, Nabriva Therapeutics's (NASDAQ:NBRV) reported sales totaled $8.24 million. Despite a ...

Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep, 2021 FinancialContent
Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
31 Aug, 2021 FinancialContent
First Week of April 2022 Options Trading For Nabriva Therapeutics (NBRV)
26 Aug, 2021 FinancialContent

Investors in Nabriva Therapeutics plc (NBRV) saw new options become available this week, for the April 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

28 Stocks Moving in Friday's Pre-Market Session
06 Aug, 2021 FinancialContent

Gainers Sphere 3D Corp. (NASDAQ: ANY) shares rose 35.4% to $4.66 in pre-market trading after the company reported an Agreement to ...

Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
05 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Acurx Pharmaceuticals Joins the Antimicrobials Working Group
05 Aug, 2021 Yahoo! Finance

The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 13 antimicrobial drug companies.

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021
22 Jul, 2021 FinancialContent
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)
14 Jul, 2021 Yahoo! Finance

Nabriva Therapeutics AG (NBRV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Nabriva Therapeutics plc (NBRV) is a NASDAQ Common Stock listed in , ,

970x250